Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02
Related news for (ELOX)
- Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update